procarbazine has been researched along with Thrombocytopenia in 41 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
Thrombocytopenia: A subnormal level of BLOOD PLATELETS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 9.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 9.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 9.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Twelve previously untreated patients with histologically documented, metastatic, malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU, and cyclophosphamide, with an objective response rate of 33%." | 7.66 | Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma. ( Dillman, RO; Green, MR; Horton, C, 1980) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 5.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 5.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 5.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Twelve patients with relapsed or refractory malignant lymphoma were treated with IMV-triple P regimen consisting of ifosfamide (IFM), mitoxantrone (MIT), vindesine (VDS), pepleomycin (PEP), procarbazine (PCZ) and prednisolone (PDN)." | 3.68 | [Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma]. ( Arai, N; Hara, A; Shirai, T; Umeda, M, 1991) |
| "Ninety-five patients with advanced non-Hodgkin's lymphoma were treated with four courses of cyclophosphamide, adriamycin, vincristine and prednisone, with or without procarbazine [CHOP(P)] chemotherapy; either 150 rad total body irradiation (for "extensive" disease) or 3,500 rad local radiation therapy (for "limited" disease); and a final four courses of CHOP(P) chemotherapy." | 3.66 | Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. ( Appelbaum, FR; Bagley, CM; Dahlberg, S; Farewell, VT; Kadin, ME; Neiman, PE; Rudolph, RH; Sullivan, KM; Thomas, ED, 1983) |
| "Twelve previously untreated patients with histologically documented, metastatic, malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU, and cyclophosphamide, with an objective response rate of 33%." | 3.66 | Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma. ( Dillman, RO; Green, MR; Horton, C, 1980) |
| "To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU." | 2.74 | High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. ( Deckert, M; Feuerhake, F; Finke, J; Ihorst, G; Illerhaus, G; Marks, R; Müller, F; Ostertag, C, 2009) |
| "The best treatment of follicular lymphoma remains to be determined because the long natural history of follicular lymphoma requires mature data for accurate analysis." | 2.70 | Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma. ( Avilés, A; Cleto, S; Díaz, N; Díaz-Maqueo, JC; García, EL; Neri, N; Talavera, A, 2001) |
| " Despite increased hematotoxicity, moderate dose escalation is safe for the majority of the patients with G-CSF assistance and standard supportive treatment." | 2.69 | Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). ( Diehl, V; Engel, C; Loeffler, M; Schmitz, S; Tesch, H, 2000) |
| "Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD)." | 2.65 | Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine. ( Bond, WH; Chenoweth, L; Einhorn, LH; Stevens, EE; Williams, SD, 1983) |
| " This side effect could be explained by a cycling of the hematopoietic stem-cells and call to some caution when androgens are used during cancer chemotherapy." | 2.64 | [Increased hematological toxicity of antineoplastic drugs with simultaneous androgenotherapy (author's transl)]. ( Barthélémy, M; Bilski-Pasquier, G; Blanc, CM; Bouchard, M; Bousser, J; Zittoun, R, 1977) |
| "Sixteen patients with Hodgkin's disease were treated with MOPP/ABVD and filgrastim support between January 1992 and March 1994." | 1.30 | G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease. ( Gustavsson, A, 1997) |
| "We report a 54-year-old patient with Hodgkin's disease who achieved a complete remission after combined modality treatment." | 1.29 | Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease. ( Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL, 1995) |
| " The optimal dosing for MV26PD remains to be determined." | 1.27 | Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902. ( Anderson, J; Bloomfield, CD; Cooper, MR; Ginsberg, SJ; Gottlieb, AJ; Hurd, DD; Lachant, NA, 1988) |
| "One patient with Hodgkin's disease involving the liver is alive at 36 months with further therapy." | 1.26 | Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease. ( Gamble, JF; Loh, KK; Rodgers, RW; Shullenberger, CC, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (48.78) | 18.7374 |
| 1990's | 11 (26.83) | 18.2507 |
| 2000's | 8 (19.51) | 29.6817 |
| 2010's | 2 (4.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rancea, M | 1 |
| Will, A | 1 |
| Borchmann, P | 1 |
| Monsef, I | 1 |
| Engert, A | 2 |
| Skoetz, N | 1 |
| Illerhaus, G | 1 |
| Marks, R | 1 |
| Müller, F | 1 |
| Ihorst, G | 1 |
| Feuerhake, F | 1 |
| Deckert, M | 1 |
| Ostertag, C | 1 |
| Finke, J | 1 |
| Zander, T | 1 |
| Nettekoven, W | 1 |
| Kraus, JA | 1 |
| Pels, H | 1 |
| Ko, YD | 1 |
| Vetter, H | 1 |
| Klockgether, T | 1 |
| Schlegel, U | 1 |
| Sieber, M | 1 |
| Bredenfeld, H | 1 |
| Josting, A | 1 |
| Reineke, T | 1 |
| Rueffer, U | 1 |
| Koch, T | 1 |
| Naumann, R | 1 |
| Boissevain, F | 1 |
| Koch, P | 1 |
| Worst, P | 1 |
| Soekler, M | 1 |
| Eich, H | 1 |
| Müller-Hermelink, HK | 1 |
| Franklin, J | 1 |
| Paulus, U | 1 |
| Wolf, J | 1 |
| Diehl, V | 2 |
| Newlands, ES | 1 |
| Foster, T | 1 |
| Zaknoen, S | 1 |
| Rodgers, RW | 1 |
| Gamble, JF | 2 |
| Loh, KK | 1 |
| Shullenberger, CC | 2 |
| Einhorn, LH | 1 |
| Williams, SD | 1 |
| Stevens, EE | 1 |
| Bond, WH | 1 |
| Chenoweth, L | 1 |
| Sullivan, KM | 1 |
| Neiman, PE | 1 |
| Kadin, ME | 1 |
| Dahlberg, S | 1 |
| Farewell, VT | 1 |
| Rudolph, RH | 1 |
| Bagley, CM | 1 |
| Appelbaum, FR | 1 |
| Thomas, ED | 1 |
| Sweet, DL | 1 |
| Golomb, HM | 1 |
| Green, MR | 1 |
| Dillman, RO | 1 |
| Horton, C | 1 |
| Somers, R | 1 |
| Carde, P | 1 |
| Thomas, J | 1 |
| Tirelli, U | 1 |
| Keuning, JJ | 1 |
| Bron, D | 1 |
| Delmer, A | 1 |
| de Bock, R | 1 |
| De Wolf-Peeters, C | 1 |
| Keunig, JJ | 1 |
| Bendandi, M | 1 |
| Zaccaria, A | 1 |
| Zinzani, PL | 1 |
| Visani, G | 1 |
| Stefanati, V | 1 |
| Cantagalli, F | 1 |
| Mancino, A | 1 |
| Macchi, S | 1 |
| Simoncelli, F | 1 |
| Tura, S | 1 |
| Canellos, GP | 1 |
| Petroni, GR | 1 |
| Barcos, M | 1 |
| Duggan, DB | 1 |
| Peterson, BA | 1 |
| Watkins, SM | 1 |
| Samuel, LM | 1 |
| Harvey, VJ | 1 |
| Mitchell, PL | 1 |
| Thompson, PI | 1 |
| Mak, D | 1 |
| Melville, P | 1 |
| Evans, BD | 1 |
| Gustavsson, A | 1 |
| Chamberlain, MC | 1 |
| Kormanik, PA | 1 |
| Abele, M | 1 |
| Leonhardt, M | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Engel, C | 1 |
| Loeffler, M | 1 |
| Schmitz, S | 1 |
| Tesch, H | 1 |
| Hamilton, VM | 1 |
| Norris, C | 1 |
| Bunin, N | 1 |
| Goldwein, JW | 1 |
| Bunin, GR | 1 |
| Lange, B | 1 |
| Meadows, AT | 1 |
| Colombi, M | 1 |
| Guffanti, A | 1 |
| Alietti, A | 1 |
| Latargia, ML | 1 |
| Vener, C | 1 |
| Maiolo, AT | 1 |
| Baldini, L | 1 |
| Neri, N | 1 |
| Avilés, A | 1 |
| Cleto, S | 1 |
| Díaz, N | 1 |
| Talavera, A | 1 |
| García, EL | 1 |
| Díaz-Maqueo, JC | 1 |
| Hansen, HH | 1 |
| Selawry, OS | 1 |
| Simon, R | 1 |
| Carr, DT | 1 |
| van Wyk, CE | 1 |
| Tucker, RD | 1 |
| Sealy, R | 1 |
| Trump, DL | 1 |
| Cowall, DE | 1 |
| Zittoun, R | 1 |
| Barthélémy, M | 1 |
| Bouchard, M | 1 |
| Blanc, CM | 1 |
| Bousser, J | 1 |
| Bilski-Pasquier, G | 1 |
| de Kreek, EJ | 1 |
| Sybesma, HB | 1 |
| Hadjiyanni, M | 1 |
| Valianatou, K | 1 |
| Tsilianos, M | 1 |
| Seitanidis, B | 1 |
| Arai, N | 2 |
| Hara, A | 2 |
| Umeda, M | 2 |
| Shirai, T | 2 |
| Lachant, NA | 1 |
| Anderson, J | 1 |
| Ginsberg, SJ | 1 |
| Cooper, MR | 1 |
| Hurd, DD | 1 |
| Bloomfield, CD | 1 |
| Gottlieb, AJ | 1 |
| Dold, U | 1 |
| Sacks, P | 1 |
| Jacobs, P | 1 |
| Gale, D | 1 |
| Lynch, SR | 1 |
| Bothwell, TH | 1 |
| Stevens, K | 1 |
| Vasantha Kumar, AR | 1 |
| Renaudin, J | 1 |
| Wilson, CB | 1 |
| Boldrey, EB | 1 |
| Enot, KJ | 1 |
| Levin, VA | 1 |
| Vermel', AE | 1 |
| Korman, NP | 1 |
| Magagina, GE | 1 |
| Raevskiĭ, IG | 1 |
| Varkarakis, MJ | 1 |
| Sampson, D | 1 |
| Brede, HD | 1 |
| Murphy, GP | 1 |
| Host, H | 1 |
| Abrahamsen, AF | 1 |
| Brunner, KW | 1 |
| Maurice, P | 1 |
| Sonntag, RW | 1 |
| Mubashir, BA | 1 |
| Fairley, GH | 1 |
| Mukherji, B | 1 |
| Oettgen, HF | 1 |
| Yagoda, A | 1 |
| Krakoff, IH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy[NCT00989352] | Phase 2 | 56 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 trials available for procarbazine and Thrombocytopenia
| Article | Year |
|---|---|
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosp | 2016 |
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Comb | 2009 |
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Topics: Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphami | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine.
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 1983 |
EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 1994 |
Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubici | 1995 |
Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lomustine; Male; Melano | 1994 |
Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
Topics: Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; | 1997 |
Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Platelets; | 2000 |
Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Combined Modality Ther | 2001 |
OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma.
Topics: Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau | 2000 |
Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dr | 2001 |
Combination chemotherapy of advanced lung cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; | 1976 |
[Increased hematological toxicity of antineoplastic drugs with simultaneous androgenotherapy (author's transl)].
Topics: Androgens; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Humans; Lymphoma; Mechlorethami | 1977 |
[On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
Topics: Carmustine; Chlorambucil; Cyclohexanes; Drug Resistance; Drug Synergism; Hodgkin Disease; Humans; Ni | 1972 |
25 other studies available for procarbazine and Thrombocytopenia
| Article | Year |
|---|---|
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Female | 2002 |
Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Dacarbazine; Doxorubicin; Drug Administra | 1980 |
Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; | 1983 |
The treatment of histiocytic lymphoma.
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Leucovorin; Leukopenia; Ly | 1980 |
Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lomustine; | 1980 |
Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Transfusion; Combined Modality | 1995 |
Predicting neutropenia after chemotherapy for lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Cy | 1993 |
G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antine | 1997 |
CCNU overdose during PCV chemotherapy for anaplastic astrocytoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neo | 1998 |
Acute myelogenous leukemia as a late complication of the multimodality therapy for Hodgkin's disease.
Topics: Adult; Biopsy; Bone Marrow; Cytarabine; Daunorubicin; Hodgkin Disease; Humans; Leukemia, Myeloid, Ac | 1977 |
[From tumors to scales].
Topics: Agranulocytosis; Humans; Immunologic Deficiency Syndromes; Leg Ulcer; Leukopenia; Male; Mechloretham | 1975 |
Prolonged thrombocytopenia after procarbazine "overdose".
Topics: Adult; Humans; Male; Procarbazine; Thrombocytopenia | 1992 |
[The COP-BLAM therapy for malignant lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophos | 1990 |
[Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Female; Hea | 1991 |
Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexametha | 1988 |
[Cytostatic therapy of bronchial carcinoma].
Topics: Antineoplastic Agents; Bronchial Neoplasms; Cyclophosphamide; Humans; Leukopenia; Methotrexate; Pall | 1972 |
Combination chemotherapy in the treatment of advanced Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzoates; Female; Hodgkin Disease; Humans; Leukopen | 1973 |
Procarbazine hydrochloride in the treatment of brain tumors. Phase 2 study.
Topics: Adolescent; Adult; Anticonvulsants; Astrocytoma; Brain Neoplasms; Child; Electroencephalography; Epe | 1974 |
[N-nitrosomethylurea in the chemotherapy of lymphogranulomatosis].
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Hematopoies | 1974 |
The immunosuppressive effect of procarbazine hydrochloride in canine renal allografts.
Topics: Administration, Oral; Animals; Benzoates; Diarrhea; Dogs; Immunosuppression Therapy; Immunosuppressi | 1972 |
Combination chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone in the treatment of malignant lymphomas.
Topics: Administration, Oral; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Injectio | 1973 |
Treatment of advanced Hodgkin's disease with combination chemotherapy.
Topics: Adult; Antineoplastic Agents; Dactinomycin; Drug Therapy, Combination; Female; Hodgkin Disease; Huma | 1973 |
The use of different drugs and combinations in the treatment of Hodgkin's disease.
Topics: Administration, Oral; Anemia; Drug Evaluation; Drug Therapy, Combination; Hodgkin Disease; Humans; I | 1973 |
Cyclic chemotherapy in lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzoates; Cyclophosphamide; Evaluation Studies as Topic; Female | 1971 |